• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

Right time to take a stab at innovations to sustain kala-azar elimination

Home > Viewpoints

Right time to take a stab at innovations to sustain kala-azar elimination

Healthcare worker handling needle
30 Jan 2023
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

By Dr Kavita Singh, South Asia Director, DNDi

First published in The Pioneer on 29 January 2023

“Act now. Act together. Invest in Neglected Tropical Diseases,” is the theme of this year’s World Neglected Tropical Diseases (NTDs) Day being observed on January 30. The Day is also marked as World Leprosy Day. NTDs is an umbrella term that refers to 20 medically diverse, communicable diseases. India is home to the world’s largest absolute burden of at least 11 major NTDs viz. ascariasis, hookworm, trichuriasis, dengue, lymphatic filariasis, trachoma, cysticercosis, leprosy, cystic echinococcosis, visceral leishmaniasis or kala-azar, and rabies.

Kavita Singh

Dr Kavita Singh Director, South Asia, Drugs for Neglected Diseases initiative (DNDi) writes for The Health Pioneer, exclusively focusing on status and elimination progress in kala-azar mostly impacting a large number of poor in the country but often overlooked by policymakers, and so a few resources are made available to address them.

Earlier this month, Union Health Minister, Dr Mansukh Mandaviya shared that kala-azar (also known as visceral leishmaniasis) cases in India fell to 834 in 2022 from 44,533 in 2007 – a 98.7% decline. India renewed its commitment of eliminating kala-azar from the country by the end of 2023. Visceral leishmaniasis is an ultimately fatal disease if not treated.

Early and effective treatment has been one of the pillars of the National Kala Azar Elimination Program of India. It is important to remember that in the past we had toxic, long, and painful treatments for kala-azar patients. The long treatment duration often led to non-compliance and possible emergence of resistance. To provide simpler treatments it was important to provide evidence-based recommendations for policy makers. Therefore a prospective, multicentre study was conducted by Drugs for Neglected Diseases initiative and its partners NCVBDC, ICMR-RMRI, KAMRC, State Health Society Bihar, and MSF in the public sector from 2012-2015.

The Government adopted a single dose treatment with Liposomal Amphotericin B which revolutionised the kala-azar treatment and helped bring the number down consistently since 2014.

While we celebrate this milestone, it is important to sustain the momentum towards kala-azar elimination. It is important we recognise the contribution made by each and every one who worked towards reaching the last mile of elimination including the policy makers who gave strategic directions to doctors, nurses, ASHAs, vector control officials, and the contribution of intersectoral ministries.

Research conducted by the DNDi in India has shown that post-kala-azar dermal leishmaniasis, a skin condition that occurs in 3-5% of treated visceral leishmaniasis patients may be an important reservoir for transmission, as are patients co-infected with HIV and the relapse visceral leishmaniasis cases. Existing diagnostics and treatments are not optimal for these patients, reminding us that still more need to be done for sustaining progress towards elimination. An outlook of fostering continual innovation of diagnostics and treatment is critical to meet the changing demands of disease elimination programmes.

In fact, neglected tropical diseases (NTDs) continue to pose significant health burdens on some of the most disadvantaged communities in our country. The task is to have a unifying theme of innovation in diagnostics, treatment, and prevention of NTDs to create solutions that are effective, relevant, locally feasible, and sustainable.

DNDi is continuing to find affordable, safe and easy treatment that will help sustain the elimination and feel an oral drug is the only way to sustain the elimination. We are continuing drug development of a new oral molecule, for visceral leishmaniasis which is presently in a phase 2 clinical trial. When we develop drugs for such diseases, it is challenging to interest pharma companies and partners wherein affordability and availability in developing nations are the end goals. Therefore, our efforts have been towards open science, partnering with research institutes taking in-kind support of pharma companies and seeking funding from various sources. So it’s a very unique model of doing drug R&D. With our frugal drug discovery and development model we have been successful in engaging Indian and international pharma companies to be the market authorization holders in the last two decades.

The National Center for Vector Borne Diseases Control includes some of these diseases which are caused by mosquitoes or sandflies, while the Ministry of Health has additional programs focused on leprosy and soil transmitted helminthiasis. The National Center for Vector Borne Disease Control presently has a kala-azar and lymphatic filariasis, both are on the elimination radar of the government, with visceral leishmaniasis being 2023 and lymphatic filariasis being 2030. So there’s a lot of implementation happening with a lot of Government and also international support. However, we need to remember that when a disease goes through a distinct programmatic phase, the requirement of the tools, whether it’s a diagnostic or treatment tool, keeps changing. So investments for these resources is the wish list of people who work in this space as we move towards sustaining elimination of visceral leishmaniasis.

As we progress, it is important to focus on optimal drugs and diagnostics that can help sustain the disease out of bay and are futuristic. As the number of cases go down, health professionals will be  out of practice and so would be the availability of drugs at Primary Health care Centers. Looking into these aspects, DNDi is developing Centres of Excellence in two districts of Bihar for the management of complicated leishmaniasis cases where we are training the health professionals in complicated diagnostic procedures and treatment regimens.

Continued vigilance will be required to sustain the gains achieved through kala-azar elimination efforts. Investing in the development of new drugs as well as diagnostics are important areas. Innovative vector control and surveillance strategies and intersectoral ministries continued contribution is crucial to sustain the elimination phase. This will also necessitate proportionate investments in research and development for new tools, training of health workers, and housing infrastructure, continued WASH advancement and quality of primary care. Commitment to eliminating the scourge of kala-azar must continue.

Photo credit: Matt Bouch-DNDi

Funding Strengthening Capacities Visceral leishmaniasis Asia India

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo